Return on Assets (ROA): 4.05%
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 4.05% is 73% below its 5-year average of 14.86%, near the low end of its 5-year range (4.05%–57.15%).
As of Monday, June 29, 2026. 30.59% below its 12-month average of 5.83%.
GEHC Return on Assets (ROA) Chart
Annual fiscal-year return on assets; no daily interpolation.
GEHC Average Return on Assets (ROA) Chart
GEHC Current vs Average Return on Assets (ROA) Chart
GEHC Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
4.05%
RETURN ON ASSETS (ROA) AVG TTM
5.83%
RETURN ON ASSETS (ROA) AVG 3Y
5.87%
RETURN ON ASSETS (ROA) AVG 5Y
14.86%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-30.59%
CURRENT VS 3Y AVG
-30.95%
CURRENT VS 5Y AVG
-72.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GEHC Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.91B | 4.05% | 5.83% | 5.87% | 14.86% |
| ResMed Inc. (RMD)vs › | $29.05B | 17.30% | 16.00% | 15.15% | 14.03% |
| Zoetis Inc. (ZTS)vs › | $31.88B | 17.44% | 17.37% | 16.33% | 15.33% |
| Biogen Inc. (BIIB)vs › | $31.89B | 4.65% | 5.11% | 6.74% | 8.29% |
| IQVIA Holdings Inc. (IQV)vs › | $31.90B | 4.67% | 4.82% | 4.76% | 4.01% |
| Veeva Systems Inc. (VEEV)vs › | $27.84B | 10.31% | 9.93% | 9.72% | 10.43% |
| Centene Corp. (CNC)vs › | $32.44B | -7.94% | -2.29% | 0.04% | 0.75% |
| DexCom, Inc. (DXCM)vs › | $27.07B | 14.03% | 11.04% | 9.26% | 8.83% |
| Medline Inc. (MDLN)vs › | $32.87B | 2.47% | 3.17% | 1.75% | 1.75% |
| Moderna, Inc. (MRNA)vs › | $26.69B | -27.80% | -24.02% | -10.32% | -0.33% |
Asset Efficiency
ROA
4.0%
ROE
14.1%
Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for GE HealthCare Technologies Inc. (GEHC)?
- The return on assets (ROA) for GEHC stock is 4.05%.
- Is GE HealthCare Technologies Inc.'s return on assets (ROA) high or low?
- The return on assets (ROA) of 4.05% is 73% below its 5-year average of 14.86%, near the low end of its 5-year range (4.05%–57.15%).
- What is the TTM average return on assets (ROA) for GE HealthCare Technologies Inc. (GEHC)?
- The TTM average return on assets (ROA) for GEHC stock is 5.83%.
- What is the 3Y average return on assets (ROA) for GE HealthCare Technologies Inc. (GEHC)?
- The 3Y average return on assets (ROA) for GEHC stock is 5.87%.
- What is the 5Y average return on assets (ROA) for GE HealthCare Technologies Inc. (GEHC)?
- The 5Y average return on assets (ROA) for GEHC stock is 14.86%.
GEHC Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 5.65% |
| 2024-12-31 | 6.02% |
| 2023-12-31 | 4.83% |
| 2022-12-31 | 6.96% |
| 2021-12-31 | 8.54% |
| 2020-12-31 | 57.15% |
| 2019-12-31 | 0.00% |
Related Metrics
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini